PortalPublikationenAnalysis of Circulating Tumor Cells in Patients with Non-Met...

Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays

Standard

Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. / Budna-Tukan, Joanna; Świerczewska, Monika; Mazel, Martine; Cieślikowski, Wojciech A; Ida, Agnieszka; Jankowiak, Agnieszka; Antczak, Andrzej; Nowicki, Michał; Pantel, Klaus; Azria, David; Zabel, Maciej; Alix-Panabières, Catherine.

in: CANCERS, Jahrgang 11, Nr. 6, 10.06.2019.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Budna-Tukan, J, Świerczewska, M, Mazel, M, Cieślikowski, WA, Ida, A, Jankowiak, A, Antczak, A, Nowicki, M, Pantel, K, Azria, D, Zabel, M & Alix-Panabières, C 2019, 'Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays', CANCERS, Jg. 11, Nr. 6. https://doi.org/10.3390/cancers11060802

APA

Budna-Tukan, J., Świerczewska, M., Mazel, M., Cieślikowski, W. A., Ida, A., Jankowiak, A., Antczak, A., Nowicki, M., Pantel, K., Azria, D., Zabel, M., & Alix-Panabières, C. (2019). Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. CANCERS, 11(6). https://doi.org/10.3390/cancers11060802

Vancouver

Budna-Tukan J, Świerczewska M, Mazel M, Cieślikowski WA, Ida A, Jankowiak A et al. Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays. CANCERS. 2019 Jun 10;11(6). https://doi.org/10.3390/cancers11060802

Bibtex

@article{a868f59089564f06901aa6f1237f79e6,
title = "Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays",
abstract = "The characterization of circulating tumor cells (CTCs) can lead to a promising strategy for monitoring residual or relapsing prostate cancer (PCa) after local therapy. The aim of this study was to compare three innovative technologies for CTC enumeration in 131 high-risk patients with PCa, before and after radiotherapy, combined with androgen deprivation. The CTC number was tested using the FDA-cleared CellSearch{\textregistered} system, the dual fluoro-EPISPOT assay that only detects functional CTCs, and the in vivo CellCollector{\textregistered} technology. The highest percentage of CTC-positive patients was detected with the CellCollector{\textregistered} (48%) and dual fluoro-EPISPOT (42%) assays, while the CellSearch{\textregistered} system presented the lowest rate (14%). Although the concordance among methods was only 23%, the cumulative positivity rate was 79%. A matched-pair analysis of the samples before, and after, treatment suggested a trend toward a decrease in CTC count after treatment with all methods. CTC tended to be positivity correlated with age for the fluoro-EPISPOT assay and with PSA level from the data of three assays. Combining different CTC assays improved CTC detection rates in patients with non-metastatic high-risk PCa before and after treatment. Our findings do not support the hypothesis that radiotherapy leads to cancer cell release in the circulation.",
author = "Joanna Budna-Tukan and Monika {\'S}wierczewska and Martine Mazel and Cie{\'s}likowski, {Wojciech A} and Agnieszka Ida and Agnieszka Jankowiak and Andrzej Antczak and Micha{\l} Nowicki and Klaus Pantel and David Azria and Maciej Zabel and Catherine Alix-Panabi{\`e}res",
year = "2019",
month = jun,
day = "10",
doi = "10.3390/cancers11060802",
language = "English",
volume = "11",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

RIS

TY - JOUR

T1 - Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays

AU - Budna-Tukan, Joanna

AU - Świerczewska, Monika

AU - Mazel, Martine

AU - Cieślikowski, Wojciech A

AU - Ida, Agnieszka

AU - Jankowiak, Agnieszka

AU - Antczak, Andrzej

AU - Nowicki, Michał

AU - Pantel, Klaus

AU - Azria, David

AU - Zabel, Maciej

AU - Alix-Panabières, Catherine

PY - 2019/6/10

Y1 - 2019/6/10

N2 - The characterization of circulating tumor cells (CTCs) can lead to a promising strategy for monitoring residual or relapsing prostate cancer (PCa) after local therapy. The aim of this study was to compare three innovative technologies for CTC enumeration in 131 high-risk patients with PCa, before and after radiotherapy, combined with androgen deprivation. The CTC number was tested using the FDA-cleared CellSearch® system, the dual fluoro-EPISPOT assay that only detects functional CTCs, and the in vivo CellCollector® technology. The highest percentage of CTC-positive patients was detected with the CellCollector® (48%) and dual fluoro-EPISPOT (42%) assays, while the CellSearch® system presented the lowest rate (14%). Although the concordance among methods was only 23%, the cumulative positivity rate was 79%. A matched-pair analysis of the samples before, and after, treatment suggested a trend toward a decrease in CTC count after treatment with all methods. CTC tended to be positivity correlated with age for the fluoro-EPISPOT assay and with PSA level from the data of three assays. Combining different CTC assays improved CTC detection rates in patients with non-metastatic high-risk PCa before and after treatment. Our findings do not support the hypothesis that radiotherapy leads to cancer cell release in the circulation.

AB - The characterization of circulating tumor cells (CTCs) can lead to a promising strategy for monitoring residual or relapsing prostate cancer (PCa) after local therapy. The aim of this study was to compare three innovative technologies for CTC enumeration in 131 high-risk patients with PCa, before and after radiotherapy, combined with androgen deprivation. The CTC number was tested using the FDA-cleared CellSearch® system, the dual fluoro-EPISPOT assay that only detects functional CTCs, and the in vivo CellCollector® technology. The highest percentage of CTC-positive patients was detected with the CellCollector® (48%) and dual fluoro-EPISPOT (42%) assays, while the CellSearch® system presented the lowest rate (14%). Although the concordance among methods was only 23%, the cumulative positivity rate was 79%. A matched-pair analysis of the samples before, and after, treatment suggested a trend toward a decrease in CTC count after treatment with all methods. CTC tended to be positivity correlated with age for the fluoro-EPISPOT assay and with PSA level from the data of three assays. Combining different CTC assays improved CTC detection rates in patients with non-metastatic high-risk PCa before and after treatment. Our findings do not support the hypothesis that radiotherapy leads to cancer cell release in the circulation.

U2 - 10.3390/cancers11060802

DO - 10.3390/cancers11060802

M3 - SCORING: Journal article

C2 - 31185699

VL - 11

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 6

ER -